Nanjing Hicin Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Nanjing Haichen Pharmaceutical Co., Ltd. was established in 2003 in the Nanjing Economic and Technological Development Zone. It is a high-tech enterprise that integrates pharmaceutical research and development, production, and marketing. The company has established GMP standard freeze-dried powder injection, small volume injection, cephalosporin powder injection, solid preparation, and API workshops. The product range covers fields such as cardiovascular, cerebrovascular, digestive, endocrine, anti infection, immune, etc., and can produce more than 60 representative varieties. We have successively launched multiple clinical essential products to the market, including Tolasemide for Injection, Cefotiam for Injection, Adenosine Monophosphate for Injection, Ganciclovir Sodium for Injection, Cefoxime Sodium for Injection, Tigecycline for Injection, and Lansoprazole for Injection. The company has established a 9600m2 Haichen New Drug Research and Development Center in Jiangsu Life Science and Technology Innovation Park, and has formed a research and development team with doctoral and master's degrees as the backbone; At the same time, we have maintained extensive project cooperation with multiple renowned domestic and international pharmaceutical research institutions such as China Pharmaceutical University, and have embarked on a path of "joint innovation of industry, academia, and research". We have applied for registration of multiple raw materials and formulation products with market potential, forming a virtuous cycle of developing, reserving, and producing the first generation. The company covers an area of 108 acres, with a registered capital of 120 million yuan, and has an annual production capacity of 30 million cephalosporin powder injections and 45 million freeze-dried powder injections. It is one of the main production bases for anti infection and freeze-dried drugs in Jiangsu Province. In 2013, the company fully acquired Zhenjiang Derui Pharmaceutical Co., Ltd., extending its industrial chain to pharmaceutical raw material intermediates and exporting raw materials to Europe, America, Japan, and other regions, laying a solid foundation for the sustainable development of Haichen Pharmaceutical. In 2013, the company completed the shareholding system transformation and became a limited liability company as a whole. The company will establish a modern corporate governance structure and build a management model centered on "shareholders' meeting, board of directors, and supervisory board". On January 12, 2017, the company successfully landed on the A-share market and was officially listed on the Shenzhen Stock Exchange ChiNext. Realized the simultaneous development of real economy and capital operation. Haichen Pharmaceutical has established and improved a sales network system throughout the country, with 28 offices, nearly a thousand terminal promotion and customer service personnel, and terminal customers from thousands of large and medium-sized hospitals. The high-quality characteristic products, high-quality sales team, professional academic promotion ability, and comprehensive sales service system have won a good reputation for the enterprise. The company has been awarded many honorary titles by the government departments, such as "Key High tech Enterprise of the National Torch Program", "High growth Small and Medium sized Enterprise in Jiangsu Province", "Advanced Enterprise of Production, Learning and Research", "Advanced Enterprise of Technological Innovation", "Integrity Enterprise of Labor and Social Security", "Informatization Driven Industrialization Demonstration Enterprise", "Enterprise of Observing Contracts and Keeping Promises", "exemplary organization of Energy Conservation and Emission Reduction in Nanjing City", and "Excellent Private Enterprise". Haichen Pharmaceutical adheres to the core values of "cultivating the pharmaceutical industry and serving the country with technology", regards "creating health and protecting all beings" as its corporate mission, and regards "Top 100 Enterprises and Centennial Brands" as its corporate vision. A new Haichen that is moving towards scale, capitalization, and internationalization will stand proudly on the banks of the Yangtze River and in the forest of medicine. |
| Headquarter | Nanjing |
| Establish Date | 1/15/2003 |
| Listed Code | 300584.SZ |
| Listed Date | 1/12/2017 |
| Chairman | Cao Yuping. |
| CEO | Cao Yuping. |
| Website | www.hicin.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
